Clinical Trial Update: Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a pragmatic adoptive cell therapy approach using an IL2 analog (ANV419) versus high-dose IL-2 after tumor-infiltrating lymphoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• ANV419
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Vall d'Hebron Institute of Oncology | Conditions: Melanoma, Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING